Zealand Pharma's Glepaglutide Receives FDA Response for Short Bowel Syndrome

Zealand Pharma's Glepaglutide Receives FDA Response for Short Bowel Syndrome

Zealand Pharma A/S, a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for its New Drug Application (NDA) for glepaglutide, a long-acting GLP-2 analog, under development for the treatment of adult patients with short bowel syndrome (SBS) with intestinal failure (IF) who are dependent on parenteral support.

The submitted NDA includes a single randomized, placebo-controlled phase 3 registration trial, which is common for a rare disease indication such as short bowel syndrome. The trial consisted of two active treatment arms, a once-weekly and twice-weekly dosing arm, respectively. Treatment with glepaglutide twice-weekly demonstrated significant and superior effects in reducing parenteral support requirements in patients with SBS-IF compared to placebo. Once-weekly glepaglutide treatment resulted in a reduction in parenteral support, but did not achieve statistical significance.

In the complete response letter, the US FDA recommended an additional clinical trial to provide further evidence to confirm the efficacy and safety of glepaglutide at the to-be-marketed dose.

“While we are certainly disappointed in the US FDA’s decision, we remain confident that the data showed robust and compelling evidence of both efficacy and safety for glepaglutide treatment. We remain firm in our belief that glepaglutide provides a significant advance in GLP-2-based therapies for the potential treatment of SBS patients who are dependent on parenteral support,” said David Kendall, Chief Medical Officer of Zealand Pharma. “We are committed to working with the agency to align on the path toward a regulatory approval, so that we can bring glepaglutide to patients in the US. In parallel, we expect to proceed with our current plans for a European Marketing Authorization Application submission in 2025.”

Zealand Pharma expects to initiate a single phase 3 trial in 2025 that is anticipated to support marketing authorizations for glepaglutide in geographies outside the US and the EU and provide further confirmatory evidence for a regulatory resubmission in the US.

Glepaglutide is a long-acting GLP-2 analog in development as a potential treatment option for short bowel syndrome. Glepaglutide is being developed as a liquid product in an autoinjector designed for subcutaneous administration, aimed to reduce, or eliminate, the need for parenteral support in people living with short bowel syndrome. The US FDA has granted orphan drug designation for glepaglutide for the treatment of short bowel syndrome.

The phase 3 program, named EASE, includes four clinical trials evaluating the potential for glepaglutide to reduce or eliminate the need for parenteral support in SBS patients with intestinal failure.

EASE-1 is a randomized, double-blind phase 3 trial that enrolled a total of 106 short bowel syndrome patients with intestinal failure who were dependent on parenteral support for at least three days per week. Patients were evenly randomized to receive treatment with 10 mg glepaglutide administered either once or twice weekly, or placebo. The primary endpoint in the trial was the absolute change in weekly parenteral support volume from baseline at 24 weeks.

In total, 102 of 106 participating patients completed EASE-1, of which 96 continued into the ongoing two-year, long-term safety and efficacy extension trial, EASE-2. EASE-2 is a randomized, double-blind trial in which SBS patients continued their assigned treatment from EASE-1 with glepaglutide 10 mg once or twice weekly. Patients who received placebo in EASE-1 were re-randomized to treatment with either glepaglutide 10 mg once or twice weekly. Patients who complete EASE-2 are eligible to participate in EASE-3, evaluating glepaglutide administered once weekly using an auto-injector.

Short bowel syndrome with intestinal failure is a complex chronic and severe condition associated with reduced or complete loss of intestinal function in which individuals are dependent on receiving fluids and nutrition parenterally. While life-sustaining, parenteral support poses significant restrictions on daily life and carries a risk of serious and life-threatening complications such as sepsis, blood clots, liver damage and renal impairment.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!